ad5.f35-hgucy2c-padre vaccine
Small Intestine Adenocarcinoma
Thomas Jefferson UniversityvaccinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Small Intestine Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEOMYCIN M.D. Anderson Cancer Center | Phase 2 | CCC |
Nivolumab M.D. Anderson Cancer Center | Phase 2 | CCC |
Ipilimumab National Cancer Institute (NCI) | Phase 2 | CCC |
HUMAN ADENOVIRUS C SEROTYPE 5 Thomas Jefferson University | Phase 2 | CCC |
Adenovirus 5/F35-Human Guanylyl Cyclase C-Padre Thomas Jefferson University | Phase 2 | CCC |
View all 23 →
Same molecule, other indications
ad5.f35-hgucy2c-padre vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →